To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.
The Neuroscience Steering Committee, led by the FNIH and its co-chairs Dr. Linda Brady, Dr. Hartmuth Kolb, and the emeritus co-chair Dr. Bill Potter, is bringing together experts in the field of neuroscience from industry, NIH, FDA, and academia to present progress to date, next steps, and key obstacles that need to be addressed in order to drive biomarker development in a multitude of neuroscience focus areas.
As part of a larger national effort to address the opioid crisis, the FNIH is leading the planning effort for a potential public-private scientific partnership that includes the NIH, FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA) and more than 30 biopharmaceutical companies.
The International Summit in Human Genetics and Genomics is a five-year initiative (2016-2020) designed to help developing nations build and expand their knowledge base, infrastructure, systems and technologies in genetics and genomics. Each fall, researchers from abroad travel to the National Institutes of Health in Bethesda, Maryland for one month of in-person training at the National Human Genome Research Institute (NHGRI). The Summit helps them to understand the prevalence and basis of genetic diseases in their nations and to address these public health challenges. The 2020 Summit will be held on August 31 - October 1, 2020.
Under Dr. Charles A. Sanders’ visionary leadership, the FNIH has influenced the course of biology and medicine over the past 20 years. At the Charles A. Sanders, M.D., Scientific Symposium, hear from scientific leaders, including Lurie Prize in Biomedical Sciences awardees, to learn more about the latest pioneering biomedical research.
The Undiagnosed Diseases Program (UDP) at the National Institutes of Health assists with diagnosing patients who have long been unable to find any diagnosis for their symptoms.
The goal of the Accelerating Medicines Partnership (AMP) is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment.
The Clinical Center In-Kind Drug Donation Program provides pharmaceuticals that are donated through the public-private partnership coordinated by the FNIH to the NIH Clinical Center.
Celebrating the 30th Anniversary of the National Institute of Nursing Research (NINR), the Advancing Science, Improving Lives symposia and scholarly events will bring together scientists, healthcare professionals and members of the public to discuss the advancements in nursing science that build the foundation of clinical nursing practice.
In 2015, the NIH became one of 17 leading institutions taking part in the Amgen Scholars Program, a training program that enables undergraduates to participate in cutting-edge research opportunities at world-class institutions.
The study was implemented using shared and harmonized protocols across the eight sites to gather an enormous amount of data (physical, cognitive assessments, diet, illness and enteric infection, socio-economic status, etc.) to enable identification and characterization of factors associated with negative impacts on a child’s growth, development and vaccine response early in life.